









Markets
/
Stocks
/
nasdaq-bmrn
/

BioMarin Pharmaceutical Inc

BMRN

55.140USD

+0.770+1.42%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

10.59BMarket Cap

16.11P/E TTM



BioMarin Pharmaceutical Inc

55.140

+0.770+1.42%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

6 / 175

Overall Ranking

56 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Buy

Current Rating

96.802

Target Price

+79.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 36.16% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 201.54.

Undervalued

The company’s latest PE is 15.81, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 195.10M shares, decreasing 7.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 18.91M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.03, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 825.41M, representing a year-over-year increase of 15.92%, while its net profit experienced a year-over-year increase of 124.43%.

Score

Industry at a Glance

Previous score

9.05

Change

-0.02



Financials

9.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 5.48, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 15.81, which is 772.75% below the recent high of 137.97 and -157.24% above the recent low of 40.67.

Score

Industry at a Glance

Previous score

5.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.34, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for BioMarin Pharmaceutical Inc is 98.00, with a high of 122.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

8.34

Change

Support & Resistance

No Data

Analyst Rating

Based on 29 analysts

Buy

Current Rating

96.802

Target Price

+78.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

BioMarin Pharmaceutical Inc

BMRN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.54, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 58.46 and the support level at 51.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.36

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.519

Sell

RSI(14)

44.468

Neutral

STOCH(KDJ)(9,3,3)

32.784

Buy

ATR(14)

1.546

High Vlolatility

CCI(14)

-46.778

Neutral

Williams %R

67.883

Sell

TRIX(12,20)

-0.275

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

54.136

Buy

MA10

55.093

Buy

MA20

56.648

Sell

MA50

57.681

Sell

MA100

57.835

Sell

MA200

61.843

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 101.61%, representing a quarter-over-quarter increase of 1.74%. The largest institutional shareholder is The Vanguard, holding a total of 18.91M shares, representing 9.85% of shares outstanding, with 2.60% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

18.92M

-1.92%

BlackRock Institutional Trust Company, N.A.

18.12M

-0.09%

PRIMECAP Management Company

Star Investors

17.77M

-2.29%

Dodge & Cox

Star Investors

14.96M

+1.42%

Viking Global Investors LP

Star Investors

10.80M

+2.75%

State Street Global Advisors (US)

8.46M

-7.12%

AQR Capital Management, LLC

2.93M

+127.94%

Geode Capital Management, L.L.C.

3.43M

+4.33%

Norges Bank Investment Management (NBIM)

3.57M

-1.37%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.49, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.